How muscle-targeting RNA vaccines work against viruses
Immunological mechanism of muscle-localizing self-replicating RNA vaccines
This study is testing a new kind of RNA vaccine designed to help your body fight off viral infections like COVID-19 by boosting your immune response, and it’s looking for participants to see how well it works and if it’s safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10781834 on NIH RePORTER |
What this research studies
This research investigates a new type of RNA vaccine that targets muscle cells to improve immune responses against viral infections, including COVID-19. By using self-replicating RNA delivered through specialized carriers, the vaccine aims to enhance the body's ability to produce antibodies and T cells while minimizing side effects. The study focuses on understanding how these vaccines can effectively stimulate the immune system without causing unwanted reactions. Patients may be involved in trials to assess the safety and efficacy of this innovative vaccination approach.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals at risk for viral infections, particularly those vulnerable to COVID-19 and other respiratory viruses.
Not a fit: Patients who are not at risk for viral infections or those who have contraindications to RNA vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against viral infections with fewer side effects.
How similar studies have performed: Previous research has shown promise in using RNA vaccines for viral infections, but this specific approach with muscle-localizing self-replicating RNA is relatively novel.
Where this research is happening
Seattle, United States
- Hdt Bio Corporation — Seattle, United States (Active)
Researchers
- Principal investigator: Kimura, Taishi — Hdt Bio Corporation
- Study coordinator: Kimura, Taishi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.